SCHEMBL21394862

SCHEMBL21394862

Cn1cc(C(=O)Nc2ccc(Oc3cccc(F)c3)cn2)ccc1=O

nearest known ligand 0.52

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
GCK P35557 5/20 0.52
MEN1 O00255 2/20 0.51
KMT2A Q03164 2/20 0.51
POLB P06746 1/20 0.51
NPC1 O15118 2/20 0.46
RAB9A P51151 2/20 0.46
ALDH1A1 P00352 1/20 0.46
PKM P14618 1/20 0.46
TSHR P16473 1/20 0.46
SMN1; SMN2 Q16637 1/20 0.46
CASP3 P42574 1/20 0.45
SENP8 Q96LD8 1/20 0.45
SENP7 Q9BQF6 1/20 0.45
SENP6 Q9GZR1 1/20 0.45
CREBBP Q92793 1/20 0.45
ABL1 P00519 1/20 0.45
RARG P13631 1/20 0.42
KIT P10721 1/20 0.42
FLT3 P36888 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29357283 1.00 GCK (0.52) GCKMEN1KMT2APOLBNPC1
SCHEMBL21395077 0.91 GCK (0.51) GCKMEN1KMT2APOLBRARG
SCHEMBL21394759 0.88 MEN1 (0.53) GCKMEN1KMT2ANPC1RAB9A
SCHEMBL29354520 0.88 MEN1 (0.53) GCKMEN1KMT2ANPC1RAB9A
SCHEMBL21395088 0.88 MEN1 (0.44) GCKMEN1KMT2APOLBNPC1
SCHEMBL29357313 0.87 GCK (0.50) GCKMEN1KMT2APOLBNPC1
SCHEMBL21384514 0.87 GCK (0.50) GCKMEN1KMT2APOLBNPC1
SCHEMBL21395074 0.86 CYP3A4 (0.53) GCKMEN1KMT2ANPC1RAB9A
SCHEMBL21394840 0.85 RAB9A (0.47) GCKMEN1KMT2ANPC1RAB9A
SCHEMBL29355464 0.85 RAB9A (0.47) GCKMEN1KMT2ANPC1RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12180221-B2 Compounds and uses thereof JANSSEN PHARMACEUTICA NV (BE) 2024-12-31 US disclosed
CN-118084800-A Compounds and uses thereof 詹森药业有限公司 2024-05-28 CN disclosed
CN-118084801-A Compounds and uses thereof 詹森药业有限公司 2024-05-28 CN disclosed
CN-112312913-B Compounds and uses thereof 詹森药业有限公司 2024-03-08 CN disclosed
US-20230078764-A1 COMPOUNDS AND USES THEREOF JANSSEN PHARMACEUTICA NV (BE) 2023-03-16 US disclosed
US-20220298168-A1 COMPOUNDS AND USES THEREOF JANSSEN PHARMACEUTICA NV (BE) 2022-09-22 US disclosed
CN-114174273-A Compounds and uses thereof 优曼尼蒂治疗公司 2022-03-11 CN disclosed
CN-112312913-A Compounds and uses thereof 优曼尼蒂治疗公司 2021-02-02 CN disclosed
WO-2020198026-A1 COMPOUNDS AND USES THEREOF YUMANITY THERAPEUTICS, INC. (US) 2020-10-01 WO disclosed
WO-2019183587-A1 COMPOUNDS AND USES THEREOF YUMANITY THERAPEUTICS, INC. (US) 2019-09-26 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230078764-A1 COMPOUNDS AND USES THEREOF NLN, BDNF, NQO1 GCK 4257/4885MEN1 191/4885KMT2A 587/4885
US-20220298168-A1 COMPOUNDS AND USES THEREOF NLN, ACHE, CLN6 GCK 3525/4885MEN1 1807/4885KMT2A 2479/4885
US-12180221-B2 Compounds and uses thereof NLN, ACHE, CLN6 GCK 3525/4885MEN1 1807/4885KMT2A 2479/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.